Director, Applied Technologies
Incyte, Delaware, United States
Proactive PhD leader focused on accelerating hit and target identification in oncology and immuno-oncology by using genome editing, disease relevant assays, and automation.
I lead the Cellular Assays and Technologies (CAT) group at Incyte, a multidisciplinary team of 9 scientists, including cell and molecular biologists. My team is focused on generating and using cellular assays to screen and identify high-value hits and progression of small molecule and antibody programs at medium and high throughput. In addition, we implement gene editing (CRISPR) and next-generation sequencing (NGS) to identify compound activity and translational biomarker discovery.
Before Incyte, I led the High Throughput Biology (HTB) group at GSK. I built this discovery team and a new lab, together with other members of the leadership team, from the ground up. I co-designed a 6.6 million dollar fully integrated lab and automated robotic system (GNF) for high throughput screening (HTS). My team was responsible for running HTS to identifying new combination therapies (DrugxDrug) for GSK's drug discovery portfolio. In addition, my group was responsible to identify gene function by genetic perturbation (CRISPR and siRNA) to identify novel drug interactions and targets.
Interests: Drug discovery, target identification, hit discovery, oncology & immune-oncology, mentorship, disease modeling, automation, and machine learning.
Disclosure information not submitted.
Wednesday, February 9, 2022
10:30 AM – 11:00 AM